Neurofibromatosis type 1 and other syndromes of the ras pathway

Monographs in Human Genetics

Volumn 16, Issue , 2008, Pages 32-45

  Stevenson, D A ^a,b   Swensen, J J ^c   Viskochil, D H ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Shriners Hospital for Children Intermountain   (United States)

^c ARUP LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870154267     PISSN: 00770876     EISSN: 16623835     Source Type: Book Series    
DOI: 10.1159/000126503     Document Type: Article

References (72)

1. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, et al: The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51-57. (Pubitemid 27274517)
2. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988;45:575-578.
3. Viskochil D, White R, Cawthon R: The neurofibromatosis type 1 gene. Ann Rev Neurosci 1993;16:183-205. (Pubitemid 23074005)
4. Bar-Sagi D: A Ras by any other name. Mol Cell Biol 2001;21:1441-1443. (Pubitemid 32156363)
5. Hingorani SR, Tuveson DA: Ras redux: rethinking how and where Ras acts. Curr Opin Genet Dev 2003;13:6-13. (Pubitemid 36143921)
6. Wennerberg K, Rossman KL, der CJ: The Ras superfamily at a glance. J Cell Sci 2005;118:843-846. (Pubitemid 40484876)
7. Rocks O, Peyker A, Kahms M, Verveer PJ, Koerner C, et al: An acylation cycle regulates localization and activity of palmitoylated Ras isoforms. Science 2005;307:1746-1752. (Pubitemid 40388611)
8. Hancock JF: Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol 2003;4:373-384. (Pubitemid 36565569)
9. Leon J, Guerrero I, Pellicer A: Differential expression of the ras gene family in mice. Mol Cell Biol 1987;7:1535-1540. (Pubitemid 17045244)
10. Plowman SJ, Williamson DJ, O'Sullivan MJ, Doig J, Ritchie AM, et al: While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable. Mol Cell Biol 2003;23:9245-9250. (Pubitemid 37499811)
11. Esteban LM, Vicario-Abejon C, Fernandez-Salguero P, Fernandez-Medarde A, Swaminathan N, et al: Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol 2001;21:1444-1452. (Pubitemid 32156364)
12. Umanoff H, Edelmann W, Pellicer A, Kucherlapati R: The murine N-ras gene is not essential for growth and development. Proc Natl Acad Sci USA 1995;92:1709-1713.
13. Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, et al: K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev 1997;11:2468-2481. (Pubitemid 27438829)
14. Johnson GL, Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-1912. (Pubitemid 35425238)
15. Schaeffer HJ, Weber MJ: Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999;19:2435-2444. (Pubitemid 29144487)
16. Malumbres M, Barbacid M: RAS oncogenes: the first 30 years. Nat Rev Cancer 2003;3:459-465. (Pubitemid 37328850)
17. Forbes S, Clements J, Dawson E, Bamford S, Webb T, et al: Cosmic 2005. Br J Cancer 2006;94:318-322. (Pubitemid 43151554)
18. Watson GH: Pulmonary stenosis, café-au-lait spots, and dull intelligence. Arch Dis Child 1967;42:303-307.
19. Partington MW, Burggraf GW, Fay JE, Frontini E: Pulmonary stenosis, café au lait spots and dull intelligence: the Watson syndrome revisited. Proc Greenwood Genet Center 1985;4:105 (abstract).
20. Allanson JE, Upadhyaya M, Watson GH, Partington M, MacKenzie A, et al: Watson syndrome: is it a subtype of type 1 neurofibromatosis? J Med Genet 1991;28:752-756. (Pubitemid 21922545)
21. Upadhyaya M, Shen M, Cherryson A, Farnham J, Maynard J, Huson SM, Harper PS: Analysis of mutations at the neurofibromatosis 1 (NF1) locus. Hum Mol Genet 1992;1:735-740.
22. Tassabehji M, Strachan T, Sharland M, Colley A, Donnai D, Harris R, Thakker N: Tandem duplication within a neurofibromatosis type I (NF1) gene exon in a family with features of Watson syndrome and Noonan syndrome. Am J Hum Genet 1993;53:90-95. (Pubitemid 23313739)
23. Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T, et al: Grouping of multiplelentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 2002;71:389-394. (Pubitemid 34800254)
24. Legius E, Schrander-Stumpel C, Schollen E, Pulles-Heintzberger C, Gewillig M, Fryns JP: PTPN11 mutations in LEOPARD syndrome. J Med Genet 2002;39:571-574. (Pubitemid 34864560)
25. Nyström AM, Annerén G, Bondeson ML: Noonan syndrome with café-au-lait spots and LEOPARD syndrome: evidence for genetic heterogeneity. Am J Hum Genet 2003;73(suppl):725.
26. Sarkozy A, Conti E, Digilio MC, Marino B, Morini E, et al: Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome. J Med Genet 2004;41:e68.
27. Wu R, Legius E, Robberecht W, Dumoulin M, Cassiman JJ, Fryns JP: Neurofibromatosis type 1 gene mutation in a patient with features of LEOPARD syndrome. Hum Mut 1996;8:51-56. (Pubitemid 26238969)
28. Noonan JA: Hypertelorism with Turner phenotype: A new syndrome with associated congenital heart disease. Am J Dis Child 1968;116:373-380.
29. Allanson JE: Noonan syndrome; in Cassidy SB, Allanson JE (eds): Management of Genetic Syndromes. Wiley, New York, 2001, pp 253-268.
30. Allanson J: The first Noonan syndrome gene: PTPN11, which encodes the protein tyrosine phosphatase SHP-2. Pediatr Res 2002;52:471.
31. Colley A, Donnai D, Evans D G R: Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis. Clin Genet 1996;49:59-64. (Pubitemid 26116815)
32. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, et al: Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001;29:465-468. (Pubitemid 34326699)
33. Lopez-Rangel E: Overlapping clinical phenotypes: the road to identifying dysmor phology signaling pathways and their associated risks. Clin Genet 2007;71:43-44. (Pubitemid 44921619)
34. Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, et al: Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet 2006;79:129-135. (Pubitemid 43927383)
35. Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, et al: Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006;38:331-336.
36. Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, et al: Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 2007;39:70-74. (Pubitemid 46026503)
37. Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, et al: Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 2007;39:75-79. (Pubitemid 46026504)
38. Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, et al: PTPN11 mutations in Noonan syndrome: Molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 2002;70:1555-1563. (Pubitemid 34533902)
39. Mohi MG, Williams IR, Dearolf CR, Chan G, Kutok JL, et al: Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 2005;7:179-191. (Pubitemid 40248343)
40. De Luca A, Bottillo I, Sarkozy A, Carta C, Neri C, et al: NF1 gene mutations represent the major molecular event underlying neurofibromatosis- Noonan syndrome. Am J Hum Genet 2005;77:1092-1101. (Pubitemid 41698528)
41. Stevenson DA, Viskochil DH, Rope AF, Carey JC: Clinical and molecular aspects of an informative family with neurofibromatosis type 1 and Noonan phenotype. Clin Genet 2006;69:246-253. (Pubitemid 43349008)
42. Hüffmeier U, Zenker M, Hoyer J, Fahsold R, Rauch A: A variable combination of features of Noonan syndrome and neurofibromatosis type 1 are caused by mutations in the NF1 gene. Am J Med Genet 2006;140 A: 2749-2756. (Pubitemid 44865061)
43. Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzhanova N, et al: An absence of cutaneous neurofibroma associated with a 3-bp in-frame deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): Evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet 2007;80:140-151. (Pubitemid 46047657)
44. Abuelo DN, Meryash DL: Neurofibromatosis with fully expressed Noonan syndrome. Am J Med Genet 1988;29:937-941.
45. Johnson JP, Golabi M, Norton ME, Rosenblatt RM, Feldman GM, et al: Costello syndrome: phenotype, natural history, differential diagnosis, and possible cause. J Pediatr 1998;133:441-448. (Pubitemid 28413632)
46. Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, et al: Germline mutations in HRAS protooncogene cause Costello syndrome. Nat Genet 2005;37:1038-1040. (Pubitemid 41486653)
47. Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA: HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A 2006;140:8-16. (Pubitemid 43054029)
48. Kerr B, Delrue MA, Sigaudy S, Perveen R, Marche M, et al: Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet 2006;43:410-405.
49. Zampino G, Pantaleoni F, Carta C, Cobellis G, Vasta I, et al: Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat 2006;28:265-272.
50. Zenker M, Lehmann K, Schulz AL, Barth H, Hansmann D, et al: Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 2007;44:131-135.
51. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, et al: Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 2006;38:294-296.
52. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, et al: Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 2006;311:1287-1290. (Pubitemid 43334718)
53. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al: Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954. (Pubitemid 34716871)
54. Timur AA, Driscoll DJ, Wang Q: Biomedicine and disease: the Klippel-Trenaunay syndrome, vascular anomalies and vascular morphogenesis. Cell Mol Life Sci 2005;62:1434-1447. (Pubitemid 40922947)
55. Eerola I, Boon LM, Mulliken JB, Burrows PE, Dompmartin A, et al: Capillary malformationarteriovenous malformation, a new clinical genetic disorder caused by RASA1 mutations. Am J Hum Genet 2003;73:1240-2149.
56. Sobata E, Ohkuma H, Suzuki S: Cerebrovascular disorders associated with von Recklinghausen's neurofibromatosis: a case report. Neurosurgery 1988;22:544-549. (Pubitemid 18095960)
57. Friedman JM, Arbiser J, Epstein JA, Gutmann DH, Huot SJ, et al: Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med 2002;4:105-110.
58. Finley JL, Dabbs DJ: Renal vascular smooth muscle proliferation in neurofibromatosis. Hum Pathol 1988;19:107-110. (Pubitemid 18065880)
59. Rosser TL, Vezina G, Packer RJ: Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology 2005;64:553-555. (Pubitemid 40189883)
60. Gibbs JB, Marshall MS, Scolnick EM, Dixon RA, Vogel US: Modulation of guanine nucleotides bound to Ras in NIH3T3 cells by oncogenes, growth factors and the GTPase activating protein (GAP). J Biol Chem 1990;265:20347-20442.
61. Laberge-Le Couteulx S, Jung HH, Labauge P, Houtteville JP, Lescoat C, et al: Truncating mutations in CCM1 encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet 1999;23:198-193.
62. Sahoo T, Johnson EW, Thomas JW, Kuehl PM, Jones TL, et al: Mutations in the gene encoding KRIT1, a Krev-1/rap 1a binding protein, cause cerebral cavernous malformations (CCM1). Hum Mol Genet 1999;8:2324-2333.
63. Zawistowski JS, Serebriiskii IG, Lee MF, Golemis EA, Marchuk DA: KRIT1 association with the integrin-binding protein ICAP-1:a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis. Hum Mol Genet 2002;11:389-396. (Pubitemid 34213612)
64. Hermanns-Sachweh B, Senderek J, Alfer J, Klosterhalfen B, Büttner R, Füzesi L, Weber M: Vascular changes in the periosteum of congenital pseudarthrosis of the tibia. Pathol Res Pract 2005;201:305-312. (Pubitemid 40668481)
65. Kuorilehto T, Kinnunen P, Nissinen M, Alanne M, Leskela HV, Lehenkari P, Peltonen J: Vasculopathy in two cases of NF1-related congenital pseudarthrosis. Pathol Res Pract 2006;202:687-690.
66. Lin AE, Birch PH, Korf BR, Tenconi R, Niimura M, et al: Cardiovascular malformations and other cardiovascular abnormalities in neurof ibromatosis 1. Am J Med Genet 2000;95:108-117.
67. Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005;37:19-24. (Pubitemid 40070934)
68. Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell 2006;124:471-484. (Pubitemid 43199434)
69. Pilarski R, Eng C: Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet 2004;41:323-326. (Pubitemid 38608513)
70. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K: The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 2005;102:8573-8578. (Pubitemid 40862777)
71. Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH: Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 2005;65:2755-2760. (Pubitemid 40490077)
72. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP: Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005;121:179-193. (Pubitemid 40546387)